secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001493152-23-003649
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma
-------------------------------------------------------------------------------

- First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.
- Study targets 30 subjects across US, UK, Australia, France; 3 arms: placebo, 20 mg, 40 mg daily for 16 weeks plus 8-week follow-up.
- Partnership with Cipla; proof-of-concept data expected by mid-2024.
- PUR1900 aims to be first approved ABPA treatment, reducing systemic side effects of oral antifungals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/0001493152-23-003649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-003649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer